In this trial, the surgical rate and R0 resection rate of patients with N1 disease were both 100%, which revealed that the choice of surgery after neoadjuvant chemotherapy and anti-PD-L1 antibody (TQB2450) therapy is feasible for N1 positive SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.